AbbVie Inc. $ABBV Shares Sold by M&G PLC

M&G PLC lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 265,899 shares of the company’s stock after selling 22,406 shares during the period. M&G PLC’s holdings in AbbVie were worth $61,689,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Norges Bank acquired a new position in shares of AbbVie in the second quarter worth $4,288,200,000. Laurel Wealth Advisors LLC raised its stake in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. lifted its holdings in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after buying an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. raised its position in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ABBV. Morgan Stanley boosted their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Finally, Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Performance

ABBV opened at $231.57 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50 day moving average price of $223.56 and a 200 day moving average price of $221.07. The company has a market cap of $409.28 billion, a PE ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm earned $2.16 earnings per share. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.